Arbor, a specialty pharmaceutical company, has announced the launch of Zinotic ES as a new treatment option for Acute Otitis Externa (AOE). Zinotic ES is an extra strength formulation of original Zinotic, intended to provide children suffering from AOE with a greater degree of pain relief and skin protection.
Zinotic ES is the company’s fourth product launch in the US, and is now available by prescription from retail pharmacies across the US.
Jarrett Disbrow, President and CEO of Arbor Pharmaceuticals, said: Zinotic has become an important AOE treatment option since its introduction, and new Zinotic ES will be a welcome addition to the Zinotic franchise as it further addresses the three AOE treatment goals with its enhanced, extra strength formulation.
The launch of Zinotic ES demonstrates the company’s ongoing dedication to enhancing pediatric medicine. Arbor will continue to build its portfolio of pediatric pharmaceuticals focused on providing novel prescription products for the most common pediatric illnesses, he added.